FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807322014> ?p ?o ?g. }

• W2807322014 endingPage "1500" @default.
• W2807322014 startingPage "1489" @default.
• W2807322014 abstract "Ixekizumab, a high-affinity monoclonal antibody, selectively targets interleukin-17A and has been shown to be efficacious in the treatment of moderate to severe psoriasis. The objective was to describe the relationship between ixekizumab concentrations and efficacy response (static Physician Global Assessment [sPGA] and the Psoriasis Activity and Severity Index [PASI) scores] after 12 weeks of ixekizumab treatment in psoriasis patients from 3 phase 3 studies. Data from 2888 psoriasis patients randomized to receive placebo or 80 mg ixekizumab every 2 weeks or every 4 weeks were analyzed. Separate logistic regression models describing the relationship between ixekizumab concentrations and sPGA or PASI scores at week 12 were used to determine the probability of patients achieving a response and to investigate the impact of various patient factors other than drug concentrations on response rates. Both dosing regimens were efficacious, with higher rates of response achieved with the higher range of observed ixekizumab concentrations after every-2-week dosing. Although higher bodyweight, palmoplantar involvement, lower baseline disease state, or high baseline C-reactive protein were associated with slightly lower response rates, the magnitude of effect of these factors on sPGA(0,1) response was small, with all subgroups able to achieve high levels of response. Other factors tested had no effect including age, sex, and antidrug antibody status. Logistic regression modeling of ixekizumab concentration and efficacy data accurately identified the proportion of responders using sPGA or PASI end points. The higher concentration ranges achieved with 80 mg every 2 weeks versus every 4 weeks were associated with higher response levels." @default.
• W2807322014 created "2018-06-13" @default.
• W2807322014 creator A5000572878 @default.
• W2807322014 creator A5006002860 @default.
• W2807322014 creator A5052807157 @default.
• W2807322014 creator A5055844533 @default.
• W2807322014 creator A5067708666 @default.
• W2807322014 creator A5078777880 @default.
• W2807322014 creator A5090839893 @default.
• W2807322014 date "2018-06-07" @default.
• W2807322014 modified "2023-10-14" @default.
• W2807322014 title "Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis" @default.
• W2807322014 cites W1912890439 @default.
• W2807322014 cites W1922692046 @default.
• W2807322014 cites W1954102524 @default.
• W2807322014 cites W1965987183 @default.
• W2807322014 cites W1982598880 @default.
• W2807322014 cites W1983469765 @default.
• W2807322014 cites W1989148061 @default.
• W2807322014 cites W2021018799 @default.
• W2807322014 cites W2041318685 @default.
• W2807322014 cites W2058734479 @default.
• W2807322014 cites W2059050919 @default.
• W2807322014 cites W2064535395 @default.
• W2807322014 cites W2066002096 @default.
• W2807322014 cites W2077508765 @default.
• W2807322014 cites W2081482161 @default.
• W2807322014 cites W2095756367 @default.
• W2807322014 cites W2103120331 @default.
• W2807322014 cites W2106686862 @default.
• W2807322014 cites W2121126920 @default.
• W2807322014 cites W2156148414 @default.
• W2807322014 cites W2171889601 @default.
• W2807322014 cites W2339525054 @default.
• W2807322014 cites W2418506270 @default.
• W2807322014 cites W2598622099 @default.
• W2807322014 cites W2605336397 @default.
• W2807322014 cites W2766193813 @default.
• W2807322014 cites W4205200442 @default.
• W2807322014 cites W4361868359 @default.
• W2807322014 doi "https://doi.org/10.1002/jcph.1268" @default.
• W2807322014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29878382" @default.
• W2807322014 hasPublicationYear "2018" @default.
• W2807322014 type Work @default.
• W2807322014 sameAs 2807322014 @default.
• W2807322014 citedByCount "10" @default.
• W2807322014 countsByYear W28073220142020 @default.
• W2807322014 countsByYear W28073220142021 @default.
• W2807322014 countsByYear W28073220142022 @default.
• W2807322014 countsByYear W28073220142023 @default.
• W2807322014 crossrefType "journal-article" @default.
• W2807322014 hasAuthorship W2807322014A5000572878 @default.
• W2807322014 hasAuthorship W2807322014A5006002860 @default.
• W2807322014 hasAuthorship W2807322014A5052807157 @default.
• W2807322014 hasAuthorship W2807322014A5055844533 @default.
• W2807322014 hasAuthorship W2807322014A5067708666 @default.
• W2807322014 hasAuthorship W2807322014A5078777880 @default.
• W2807322014 hasAuthorship W2807322014A5090839893 @default.
• W2807322014 hasConcept C126322002 @default.
• W2807322014 hasConcept C142724271 @default.
• W2807322014 hasConcept C151956035 @default.
• W2807322014 hasConcept C203014093 @default.
• W2807322014 hasConcept C204787440 @default.
• W2807322014 hasConcept C27081682 @default.
• W2807322014 hasConcept C2776260265 @default.
• W2807322014 hasConcept C2777011040 @default.
• W2807322014 hasConcept C2777288759 @default.
• W2807322014 hasConcept C2779745271 @default.
• W2807322014 hasConcept C2779786854 @default.
• W2807322014 hasConcept C2780564577 @default.
• W2807322014 hasConcept C67761136 @default.
• W2807322014 hasConcept C71924100 @default.
• W2807322014 hasConcept C90924648 @default.
• W2807322014 hasConceptScore W2807322014C126322002 @default.
• W2807322014 hasConceptScore W2807322014C142724271 @default.
• W2807322014 hasConceptScore W2807322014C151956035 @default.
• W2807322014 hasConceptScore W2807322014C203014093 @default.
• W2807322014 hasConceptScore W2807322014C204787440 @default.
• W2807322014 hasConceptScore W2807322014C27081682 @default.
• W2807322014 hasConceptScore W2807322014C2776260265 @default.
• W2807322014 hasConceptScore W2807322014C2777011040 @default.
• W2807322014 hasConceptScore W2807322014C2777288759 @default.
• W2807322014 hasConceptScore W2807322014C2779745271 @default.
• W2807322014 hasConceptScore W2807322014C2779786854 @default.
• W2807322014 hasConceptScore W2807322014C2780564577 @default.
• W2807322014 hasConceptScore W2807322014C67761136 @default.
• W2807322014 hasConceptScore W2807322014C71924100 @default.
• W2807322014 hasConceptScore W2807322014C90924648 @default.
• W2807322014 hasFunder F4320307758 @default.
• W2807322014 hasIssue "11" @default.
• W2807322014 hasLocation W28073220141 @default.
• W2807322014 hasLocation W28073220142 @default.
• W2807322014 hasOpenAccess W2807322014 @default.
• W2807322014 hasPrimaryLocation W28073220141 @default.
• W2807322014 hasRelatedWork W2073564793 @default.
• W2807322014 hasRelatedWork W2752688736 @default.
• W2807322014 hasRelatedWork W3015166491 @default.
• W2807322014 hasRelatedWork W3084176453 @default.

• next